Stockscreener 앱 받기
1.20
9.09%
0.10
시간 외 거래:
1.22
0.02
+1.67%
전일 마감가:
$1.10
열려 있는:
$1.305
하루 거래량:
12.56M
Relative Volume:
23.36
시가총액:
$284.86M
수익:
-
순이익/손실:
$-12.70M
주가수익비율:
-2.2463
EPS:
-0.5342
순현금흐름:
$-12.36M
1주 성능:
+10.09%
1개월 성능:
+9.09%
6개월 성능:
+16.50%
1년 성능:
+10.09%
1일 변동 폭
$1.05
$1.32
1주일 범위
$1.015
$1.32
52주 변동 폭
$0.66
$2.10
엔라이벡스 Stock (ENLV) Company Profile
Compare ENLV vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENLV
Enlivex Ltd
|
1.20 | 261.12M | 0 | -12.70M | -12.36M | -0.5342 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
엔라이벡스 Stock (ENLV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-02 | 재확인 | H.C. Wainwright | Buy |
엔라이벡스 주식(ENLV)의 최신 뉴스
Envilex Therapeutics (ENLV) Reports Strong FY GAAP EPS - GuruFocus
Enlivex Soars After FDA Approval for Allocetra Trial - StocksToTrade
Enlivex Stock Boosted by FDA Approval for Allocetra in Osteoarthritis Trials - timothysykes.com
Enlivex shares jump after earnings as treasury gains boost results - MSN
Enlivex Allocetra Takes A Leap as FDA Clears Phase 2b Trial for Osteoarthritis - timothysykes.com
Enlivex Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Enlivex Q4 2025 sees stock surge on treasury gains - Investing.com
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48 - Bitget
Enlivex Posts $1.23B Profit (Net Income) For Fiscal 2025 - Benzinga
Enlivex Posts $1.23 Billion Profit for 2025 on Treasury Asset Gains - TipRanks
Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS - MarketBeat
Enlivex Ltd. Reports $1.23 Billion Net Income for 2025 Driven by Treasury Asset Appreciation - Quiver Quantitative
Biotech–crypto hybrid Enlivex (NASDAQ: ENLV) outlines RAIN treasury risks and funding needs - Stock Titan
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted ... - Bluefield Daily Telegraph
Enlivex (NASDAQ: ENLV) nets $1.23B in 2025 on digital treasury gains - Stock Titan
Treasury gains push Enlivex to $1.23B profit, $2.31B in assets - Stock Titan
Strategic Move: Enlivex Allocates $21 Million for RAIN Token Acquisition Amid Share Buyback - MEXC
Enlivex Raises $21 Million to Expand RAIN Token Treasury Holdings - Blockonomi
Enlivex Raises $21M to Expand RAIN Token Treasury and Biotechnology Pipeline - MoneyCheck
Enlivex Secures $21M Funding to Boost RAIN Treasury Strategy - CoinCentral
Off The Hook Yachts and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Enlivex stock rating held at Hold by D. Boral Capital after debt deal - Investing.com Australia
Enlivex Funding Rounds, Token Sale Review & Tokenomics Analysis - CryptoRank
Enlivex secures $21M debt financing, buys more RAIN tokens - Investing.com
Enlivex Secures $21 Million Convertible Debt, Expands RAIN Token Holdings and Launches $20 Million Buyback - TipRanks
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program - The Manila Times
Enlivex (Nasdaq: ENLV) adds $21M financing and $20M share repurchase plan - Stock Titan
Backed by $21M debt, Enlivex buys 3B more RAIN tokens at discount - Stock Titan
Enlivex secures $21M debt financing, buys more RAIN tokens By Investing.com - Investing.com Canada
FDA clears Enlivex knee osteoarthritis therapy for phase 2b trial By Investing.com - Investing.com Australia
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis - Stocktwits
Enlivex (ENLV) Gains FDA Approval for Osteoarthritis Drug Trial - GuruFocus
Enlivex Therapeutics announces FDA clearance of Allocetra new drug application - TipRanks
Enlivex Gets Investigational New Drug Clearance in US for Phase 2b Trial of Knee Osteoarthritis Treatment - marketscreener.com
Enlivex Wins FDA IND Clearance for Global Phase 2b Trial of Allocetra in Knee Osteoarthritis - TipRanks
FDA clears Enlivex (Nasdaq: ENLV) Phase 2b Allocetra trial in knee osteoarthritis - Stock Titan
FDA clears Enlivex study for knee arthritis drug in older adults - Stock Titan
Enlivex Therapeutics Tokenized Stock (Ondo) price today, ENLVon to USD live price, marketcap and chart - CoinMarketCap
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Monday - Defense World
CEO Change: How does Enlivex Therapeutics Ltd score in quality rankings2026 Volume Leaders & AI Optimized Trade Strategies - baoquankhu1.vn
Aug Rallies: Can Enlivex Therapeutics Ltd sustain earnings growthPrice Action & Community Verified Watchlist Alerts - baoquankhu1.vn
AI Stocks: Is Enlivex Therapeutics Ltd in a long term uptrend2026 Bull vs Bear & Real-Time Price Movement Reports - baoquankhu1.vn
Enlivex Ltd.: Fundamental Analysis and Financial Ratings | 1BT | IL0011319527 - marketscreener.com
ENLV (NASDAQ: ENLV) trims ATM program to $250M, prior sales noted - Stock Titan
Enlivex Ltd.: Fundamental Analysis and Financial Ratings | ENLV | IL0011319527 - marketscreener.com
EBIT per share of Enlivex Ltd. – LS:A119KH - TradingView
Nasdaq Moves: Can Enlivex Therapeutics Ltd reach all time highs this year - baoquankhu1.vn
Sentiment Recap: How does Enlivex Therapeutics Ltd score in quality rankings2026 Spike Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Enlivex (ENLV) CEO details direct holdings of shares and stock options - Stock Titan
Enlivex (ENLV) CFO discloses initial share and option holdings - Stock Titan
Enlivex (ENLV) director Hart Gili reports option and share holdings - Stock Titan
엔라이벡스 (ENLV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):